Navigation Links
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Date:4/20/2009

tection when given within 12 hours of an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our first Phase I human safety study demonstrated that Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin. This second study will continue to expand our safety database and provide additional pharmacokinetic data."

Dr. Posillico added, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited about Anthim because the results of all of our studies show that treatment with Anthim has the potential to provide significant therapeutic benefit for people infected with anthrax in a bioterrorism emergency." Currently antibiotics represent the only therapeutic option for anthrax infection. Antibiotics target the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, antibiotic resistant strains of anthrax could be used in a bioterror attack, making the medical need for anti-toxin therapy even more acute.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. The National Institutes of Health and the Department of Defense have awarded Elusys a total of $34 million for the development of Anthim, of which $12 million was awarded in September 2007 under contract #HHSN272200700035 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Hea
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Another LNA-based RNA Inhibitor Enters Clinical Trials
7. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
8. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 Pixcelldata, ... collaboration software has announced a major new deal with ... by renowned pathology expert, Dr. Marius Nap . ... the 26th European Congress of Pathology which is taking ... ExCeL Arena, London where Pixcelldata ...
(Date:8/28/2014)... WILMINGTON, Del. , Aug. 28, 2014  Rigrodsky & Long, ... shares of Lannett Company, Inc. (NYSE: LCI )? , ... between September 10, 2013 and July 16, 2014, inclusive? , ... Inc.? , Do you want to discuss your rights? ... former Special Assistant United States Attorney, Timothy J. MacFall , ...
(Date:8/28/2014)... 28, 2014  Decision Resources Group finds that ... strongly through 2022 at a compound annual growth ... largely supported by strong population growth and a ... imaging procedures. The Indian government,s greater investment in ... purchase or upgrade diagnostic imaging equipment. ...
Breaking Medicine Technology:Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 2Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 3
... NEW YORK, Dec. 2 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has granted Fast Track designation ... anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, ... , The Fast Track program of the FDA is ...
... BIRMINGHAM, Ala., Dec. 2 Adults are more likely to ... over, the odds of losing vision are one in three, whereas the ... odds of a woman developing breast cancer are one in nine. ... risk of injuries, depression and inability to complete daily tasks. , Vision ...
Cached Medicine Technology:Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2
(Date:8/29/2014)... Dr. Parsa Mohebi M.D. has developed new techniques that ... results in hair transplantation. One of these techniques is ... method that harvests facial hair for transplanting to the patient’s ... hair loss classification is 5 and above achieve reasonable coverage ... for those advanced hair loss patients who may not have ...
(Date:8/29/2014)... A recent article discusses the ... Tokyo clothing store for men with gynecomastia, or male breasts, ... diminishing their problem. Board-certified plastic surgeon Dr. Chasan is familiar ... many people only associate male breasts with men who are ... men of all ages, often starting in adolescence. Men with ...
(Date:8/29/2014)... August 29, 2014 Healthpointe is ... University Physical Therapy students via Clinical Rotations. ... will be shadowing Healthpointe providers and specialists throughout ... to develop clinical experience and learn professional preparation. ... will gain insight into several patient care techniques ...
(Date:8/29/2014)... Charleston, SC (PRWEB) August 29, 2014 Highly regarded ... special reports on important hearing health topics. The four reports are ... The Secrets to Hearing Aid Success , ... Aid , Understanding Auditory Processing Disorder in Children ... 4 topics because there is a lot of confusion and misinformation ...
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- Astronauts may ... appears to disrupt human immune systems, a new study ... any long missions to asteroids, the moon and Mars ... flu while in space can be dangerous, NASA researchers ... cells in the blood of International Space Station crew ...
Breaking Medicine News(10 mins):Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2
... Oct. 16 Speaker Nancy Pelosi,Senate Majority Leader Harry ... Simon, Families USA, Easter Seals, and other advocates at ... to override the,President,s veto of the Children,s Health Insurance ... Pollack, to Families USA, to Easter Seals, and to ...
... DEXTER, Mich., Oct. 16 ReCellular, Inc., ... used wireless phones and,accessories, today announced it ... Cellular ( http://www.consumercellular.com ), one of,the nation,s ... to,collect wireless handsets for recycling from their ...
... PARK, N.J., Oct. 16 HLTH Corporation,(Nasdaq: HLTH ... for,the three months ended September 30, 2007 at approximately ... addition, as previously announced, HLTH Corporation,s 84% owned,subsidiary, WebMD ... will also,release their financial results for the three months ...
... /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ASPV ; ... of approximately US $62 million for the third,quarter ... in the third quarter,of 2006. As previously ... Wednesday, October 31, 2007. The Company will hold ...
... an easy-to-swallow caplet., VANCOUVER, Wash., Oct. 16 ... Pro-Biotic Acidophilus, a combination of,five types of beneficial ... immune system with the good stuff from yogurt ... is growing public and scientific,interest in probiotics. Recent ...
... In the November 1st issue of G&D, Dr. Michael ... the gene Meis1 as a critical player in the ... MLL leukemia. , Mixed lineage leukemia (MLL) is a ... prevalent acute lymphoblastic leukemia (ALL) by the presence of ...
Cached Medicine News:Health News:Pelosi: In 48 Hours, Congress Must Choose Between Meeting the Needs of America's Children or Not 2Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 2Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 3Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 4Health News:Northwest Natural Products Introduces AccuFlora(R) 2
Buffer solution is needed to calibrate pH catheters. The specific chloride ion concentration in the Medtronic buffers is required for proper function of your Medtronic pH measurement system. Buffer s...
pHix Strips easily fix the catheter on the nose and are made of microporous tape allowing the skin to breathe....
... designed using established technology providing a ... ,Working with pH catheters with ... multi-use catheter is used the Hellige ... the skin.,NOTE: ,Medtronic pH measurement systems ...
... single-use pH catheters are efficient, economical, ... allow greater patient comfort during the ... measurement systems have been designed to ... an accurate room-temperature calibration. The temperature ...
Medicine Products: